To determine whether metastasis to brain is associated with altered expression patterns of integrins, we investigated the expression of avb3, avb5, avb6 and avb8 integrins in primary malignancies and metastases to brain of breast, lung and renal carcinomas and in malignant melanoma. Inhibitors of av integrins are currently in clinical trials for glioblastoma. The role of integrins in the process of brain metastasis from other human tumors is unknown. Immunohistochemistry with novel integrin subtype specific rabbit monoclonal antibodies was performed on tissue microarrays of archival material of surgical biopsies taken from primary tumors and brain metastases. Integrin avb3 expression was increased in brain metastases compared to primary tumors of breast adenocarcinoma, non-small cell lung cancer, renal clear cell cancer and malignant cutaneous melanoma (all p < 0.01). Similarly, integrin avb8 expression was increased in brain metastases compared to primary tumors of breast cancer (p < 0.0001), lung cancer (p < 0.01) and renal cancer (p < 0.0001), with a similar trend in metastatic melanoma. Integrin avb5 was expressed in most primary tumors (98% breast cancer; 67% lung cancer; 90% renal cancer; 89% melanoma) and showed a stronger expression in brain metastases compared to primary tumors from lung cancer and melanoma (p < 0.05). Also integrin avb6 expression was increased in brain metastases compared to primary breast cancer (p < 0.001). Conclusions: The stronger av-integrin expression in brain metastases, especially of avb3 and avb8 integrins, suggests that certain av integrin are involved in the process of brain metastasis. av Integrins may be therapeutic targets for patients with metastatic cancer in brain.Some 45% of cancer patients develop brain metastases during the course of their illness, with 98,000 to 170,000 new cases diagnosed each year in the U.S. alone. 1 There is an increasing prevalence of brain metastases, as primary treatments have become more effective, and people with cancer live longer after initial treatment. Changes in cellular protein levels accompany the metastatic processes, but the molecular details and drivers of the process are unknown for most cancers. These changes allow tumor cells to escape the primary, and to attach and survive at foreign sites, 2,3 which strongly implicates a role for an altered activity of integrins during tumor progression. Integrins are a family of heterodimeric transmembrane glycoproteins that classically bind the extracellular matrix (ECM) to influence cell attachment, motility, cell proliferation, invasion and tumor cell metastasis. 4,5 Several integrin-dependent mechanisms may influence metastasis. Integrins influence tumor cell survival 6 and migration and invasive processes, 7 thereby affecting tumor growth and metastasis. 8 Different integrins in different cellular contexts can either enhance survival or initiate apoptosis. 6,9,10 Although integrins cannot transform cells, several cooperate with oncogenes or receptor tyrosine kinases 6 to influence tum...